You are here: Home » PTI Stories » National » News
Business Standard

Alembic Pharma gets USFDA nod for Febuxostat tablets

Topics
Health Medical Pharma

Press Trust of India  |  New Delhi 

Drug firm Alembic Pharmaceuticals Tuesday said it has received approval from the US health regulator for Febuxostat tablets, used to lower high levels of uric acid in adults who have gout.

The approved product is therapeutically equivalent to the reference listed drug Uloric tablets of Takeda Pharmaceuticals U.S.A., Inc.

The company has received approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Febuxostat tablets in the strengths of 40 mg and 80 mg, Alembic Pharmaceuticals said in a filing to BSE.

Quoting IQVIA data, Alembic Pharma said Febuxostat tablets have an estimated market size of USD 578 million for twelve months ending December 2018.

The company currently has a total of 98 ANDA approvals (87 final approvals and 11 tentative approvals) from USFDA, it added.

Alembic had earlier received tentative approval for this ANDA from the US health regulator.

Shares of Alembic Pharmaceuticals were trading 3.86 per cent higher at Rs 523 apiece on the BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, July 02 2019. 10:50 IST
RECOMMENDED FOR YOU